Ovarian cancer

Kerbrat P, P Kerbrat, Lhommé C, C Lhommé, Béatrice Fervers, B Fervers, Guastalla JP, J P Guastalla, L. Thomas, Thomas L, Tournemaine N, N Tournemaine, J P Basuyau, Basuyau JP, C Cohen-Solal, Cohen-Solal C, P Duvillard, Duvillard P, Bachelot T, T Bachelot, I Ray, Ray I, Voog E, E Voog, J Dauplat, Dauplat J, French National Federation of Cancer (FNCLCC)
British journal of cancer · 2001 · vol. 84 Suppl 2(Suppl 2) , pp. 18–23 · doi:10.1054/bjoc.2000.1758 · PMID:11355964 · PMC2408843
Guideline OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-09-29 ⓘ

The provided text does not contain sufficient information to summarize the paper's findings or its relation to endometriosis and adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-29 · read from full text ⓘ

This brief editorial overview highlights the rising incidence of ovarian cancer and discusses current diagnostic challenges, particularly the lack of effective early detection methods. It reviews existing screening strategies, including transvaginal ultrasound and serum biomarkers like CA-125, while noting their limitations in sensitivity and specificity for early-stage disease. The text emphasizes the need for improved therapeutic approaches to reduce mortality rates associated with this malignancy. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 543 characters · extracted from oa-html · click to expand
Full Text The Full Text of this article is available as a PDF (58.4 KB). As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Learn more: PMC Disclaimer | PMC Copyright Notice . 2001 May;84(Suppl 2):18–23. doi: 10.1054/bjoc.2000.1758 The Full Text of this article is available as a PDF (58.4 KB). - View on publisher site - PDF (58.4 KB) - PERMALINK

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Medical Oncology Ovarian Neoplasms Ovarian Neoplasms Chemotherapy, Adjuvant Combined Modality Therapy Documentation Documentation Female France France Humans Incidence Mass Screening Mass Screening Medical Oncology Neoplasm Staging Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T20:59:53.382863+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-4.0